Avidity Biosciences specializes in a pioneering RNA therapeutic platform called Antibody Oligonucleotide Conjugates (AOCs), targeting rare muscular dystrophies with three key clinical-stage programs. Recent progress includes an FDA-authorized Managed Access Program for its lead Duchenne muscular dystrophy candidate and a pending merger with Novartis, alongside a planned spin-off of early-stage cardiovascular assets into Atrium Therapeutics. The success of these strategic moves, combined with clinical progress, underpins the company’s growth potential but also introduces execution and regulatory risks. Avidity maintains a robust cash position with no debt, while operating losses have increased significantly as it advances its pipeline.